Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 14-17 January 2019

Share

News 18/01/2019

At its monthly meeting, EMA’s safety committee ([PRAC](https://www.ema.europa.eu/en/glossary/prac)) carried out its broad range of responsibilities, which cover all aspects of the risk management of the use of medicines: assessment of [safety signals](https://www.ema.europa.eu/en/glossary/safety-signal), [risk management plans](https://www.ema.europa.eu/en/glossary/risk-management-plan), [periodic safety update reports](https://www.ema.europa.eu/en/glossary/periodic-safety-update-report) and post-authorisation safety studies.

The Committee did not start or conclude any [referral](https://www.ema.europa.eu/en/glossary/referral) procedures. More information on all safety reviews currently under evaluation is provided in the ‘Ongoing [referrals](https://www.ema.europa.eu/en/glossary/referral)’ table.

Information on all topics discussed by the [PRAC](https://www.ema.europa.eu/en/glossary/prac) is available in the agenda below. A record of the discussions held this week will be provided in the minutes of this meeting, which will be published following the next [PRAC](https://www.ema.europa.eu/en/glossary/prac" \t "_blank" \o "Pharmacovigilance Risk Assessment Committee -  the committee that is responsible for assessing all aspects of the risk management of medicines for human use.   More information can be found under 'Pharmacovigilance Risk Assessment Committee (PRAC)'.)meeting in February.